JUBLINGREA Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

Jubilant Ingrevia faces a pivotal end to its fiscal year as it navigates pricing headwinds in its core Specialty Chemicals and Nutrition segments. Investors will be looking for updates on the integration of its newly acquired Remidex Pharma and the ramp-up status of its Bharuch CDMO facility to gauge the company's progress toward its long-term Pinnacle 345 growth strategy.

JUBLINGREA Q4 Results Date and Time

The board of directors will meet on May 26, 2026, to consider the audited financial results and recommend dividend for FY2026.

An analyst call is scheduled for May 26, 2026, to discuss the FY26 results.

What to expect from JUBLINGREA's Q4 FY26 results

In its most recently reported quarter, Jubilant Ingrevia posted revenue of Rs. 1,051 Cr, PAT of Rs. 47 Cr, and an EBITDA margin of 13%. Specialty Chemicals volume growth of 10-12% annually has served as a key offset to pricing declines observed over the last 9 months. Management continues to prioritize its Pinnacle 345 strategy, which aims for a 3x revenue and 4x EBITDA increase by FY'30 from the FY'25 baseline. The upcoming results will clarify the impact of persistent demand-supply imbalances in the agrochemical sector and the progress of the Rs. 366 Cr capex deployed during 9M FY26.

Key Things To Watch

Performance vs Guidance Tracking

• EBITDA CAGR target of ~20% — Q3 FY26 performance showed -8% YoY decline
• Specialty Chemicals margin target of 25%+ — currently at 25% in Q3 FY26
• FY26 Capex guidance of ~Rs. 600 Cr — 9M actual spend reached Rs. 366 Cr
• Nutrition margin target of 16-18% — currently at 11% in Q3 FY26

Strategic and Operational Focus

• Integration milestones for Remidex Pharma following the Rs. 16.5 Cr acquisition
• Bharuch CDMO facility utilization progress toward the 70-80% target
• Conversion status of 7+ advanced discussion opportunities representing Rs. 900 Cr in peak revenue potential